Pages

Tuesday, November 10, 2015

Lowering Blood Pressure Target May Lead To Lower Rates Of CV Events.

The CBS Evening News (11/9, story 9, 1:25, Pelley) reported that “a new study that says sharply lower blood pressure leads to significantly longer lives.” On ABC World News(11/9, story 8, 1:00, Muir), ABC’s Dr. Richard Besser reported, “The results were so startling, they stopped the study...early.”

In a 1,300-word article, the New York Times (11/10, Kolata, Subscription Publication) reports that investigators found that “among the 9,361 hypertension patients followed for an average of 3.2 years, there were 27 percent fewer deaths (155 compared with 210) and 38 percent fewer cases of heart failure (62 compared with 100) among patients who achieved the systolic pressure target of 120 than among those who achieved the current 140 target.” Altogether, “there was a 25 percent reduction — 243 compared with 319 — in people who had a heart attack, heart failure or stroke or died from heart disease, Dr. Paul K. Whelton, a principal investigator for the study, said.” The findings were presented at the American Heart Association meeting and published in the New England Journal of Medicine.

The AP (11/10, Marchione) reports that “too-low blood pressure, fainting episodes and more worrisome, kidney problems were 1 percent to 2 percent higher in the lower pressure group.” However, “falls that cause injury due to lightheadedness were not more common, as had been feared especially for older people.”

The Seattle Times (11/10, Aleccia) reports that “the study, dubbed the Systolic Blood Pressure Intervention Trial — or SPRINT — was stopped in September, nearly two years early, when it became clear that radically lowering blood pressure for many people older than 50 helped prevent heart attacks and other heart problems and deaths.”




Friday, October 30, 2015

Reduced-Fat Diets No More Effective Than Other Weight-Loss Diets, Meta-Analysis Suggests.


Bloomberg News (10/29, Tozzi) reports that a meta-analysis published Oct. 29 in The Lancet Diabetes & Endocrinology “finds reducing fat isn’t any more effective for losing weight than other diets.”

The CBS News (10/29, Marcus) website reports that after analyzing data from “53 studies” including “more than 68,000 adults,” researchers found that “reduced-fat diets only led to more weight loss when compared with no diet at all.” Individuals “on low-carbohydrate diets lost substantially more weight than those who went the low-fat route.”

TIME (10/29, Sifferlin) reports that the study authors concluded that “public health guidelines should stop recommending low-fat diets for weight loss, stressing that more research is needed to find what strategy is most effective and able to be maintained.”

Also covering the story are CNBC (10/29, Ferris), Vox, HealthDay (10/29, Doheny), AFP (10/29), the Telegraph (UK) (10/29, Donnelly), and The Guardian (UK) (10/29, Boseley).

Friday, October 23, 2015

FDA Warns Hepatitis C Drugs Could Cause Severe Liver Damage To Patients With Underlying Liver Disease.

The Wall Street Journal (10/23, Loftus, Subscription Publication) reports that the Food and Drug Administration issued a warning on Thursday that AbbVie Inc.’s Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) and Technivie (ombitasvir/paritaprevir/ritonavir) may cause severe liver damage to patients who have an underlying liver disease.

The Washington Post (10/23, Dennis) reports that the FDA said it had received reports of at least 26 cases since late 2014 of patients “who either died or had to undergo liver transplantation” after taking the hepatitis C drugs, with the liver damage occurring in the first month of treatment. According to the Post, the agency “will require AbbVie to add new warnings to the safety labels of the drugs for patients who already have advanced liver disease linked to hepatitis C” and “urged doctors to closely monitor patients taking the drugs for symptoms of worsening liver disease.” Bloomberg News (10/23, Bloomfield) and the AP (10/23, Perrone) also cover the story.

Wednesday, October 7, 2015

Late Bedtimes May Be Linked To Weight Gain Over Time.


On its website, CBS News (10/3, Welch) reported that research published in Sleep suggests that “going to bed later during the workweek is associated with weight gain over time.” Investigators looked at “data on more than 3,300 teens and young adults recorded at different intervals over the course of about 15 years.”

HealthDay (10/3, Preidt) reported that the investigators “found that each extra hour of late bedtime was associated with a more than two-point increase in body mass index (BMI).” The data indicated that the association “between late bedtimes and BMI increase was not significantly affected by total sleep time, amount of exercise, or time spent in front of computers or televisions.”

Wednesday, September 30, 2015

Calcium Supplements May Not Strengthen Bones In Women Under 80, Study Finds.



David Muir reported on ABC World News (9/29, story 10, 0:30, Muir) that new research finds “taking daily calcium supplements does little to strengthen bones in women under 80.” Muir reported, “Only women over 80 and in nursing homes saw hip fractures decrease by 23 percent.”

Correspondent Rehema Ellis reported on NBC Nightly News (9/29, story 7, 2:15, Holt) that investigators “concluded that most people over 50 won’t get stronger bones if they increase their calcium intake.” The findings were published in the British Medical Journal.

Meanwhile, NBC News (9/30) reports on its website that the “extra calcium doesn’t go to strengthen bones but instead can build up in the arteries, causing heart disease, or in the kidneys, causing kidney stones.”

TIME (9/30, Sifferlin) reports the results from the meta-analysis “suggest that clinicians, advocacy organizations and health policymakers should not recommend increasing calcium intake for fracture prevention either with calcium supplements or through dietary sources,” the New Zealand researchers wrote. TIME adds that the “new results also fall in line with the guidance provided by the United States Preventative Services Task Force in 2013,” which, based on the evidence available, ultimately concluded that “post-menopausal women should not take daily supplements.”

Also covering the story are HealthDay (9/30), LiveScience(9/30), and the Telegraph (UK) (9/30).


Friday, September 18, 2015

Diabetes Medication May Reduce Deaths From Cardiovascular Disease, Study Suggests.

The New York Times (9/18, B2, Pollack, Subscription Publication) reports that “for the first time, a widely used modern diabetes” medication “has been shown to reduce deaths from cardiovascular disease, a long-sought goal of treatment, researchers announced” yesterday. The research(9/18) was presented at the annual meeting of the European Association for the Study of Diabetes and published in The New England Journal of Medicine.

On its website, NBC News (9/17) reports that the medication, “called Jardiance [empagliflozin], lowered heart disease deaths by 38 percent and deaths from any cause by 32 percent over three years.”

The AP (9/18, Johnson) reports that the findings “were particularly striking because nearly four-fifths of the participants were already taking standard medicines to control blood sugar, blood pressure and cholesterol, plus taking either Jardiance or a” placebo.

CDC Says Flu Vaccine May Be More Effective This Year.

The CBS Evening News (9/17, story 12, 1:45, Pelley) reported that this year’s influenza vaccine may be more effective than last year’s. According to Dr. Jon Lapook, “Last year, the vaccine was only 23 percent effective because the predominant strain mutated after the vaccine had already been manufactured.” CDC “officials say this year’s flu vaccine is well-matched right now to circulating viruses.”

The Los Angeles Times (9/18, Kaplan) reports that this year, “flu watchdogs at the CDC have scrutinized 199 flu specimens collected in the United States and elsewhere between May 24 and Sept. 5.” They found that “the majority of those specimens – 118 of them – were H3N2 viruses, and all of them were built in a way that should make them vulnerable to this year’s vaccines.”

McClatchy (9/18, Mueller) reports that “by including components of H3N2 in this season’s flu vaccine, health care professionals hope to raise vaccine effectiveness against predominant strains back up to the 50 to 60 percent range.”

The AP (9/18, Neergaard) reports that, “all told, at least 171 million doses of flu vaccine are expected this year.” Meanwhile, Dr. Tom Frieden, director of the Centers for Disease Control and Prevention, said “it doesn’t matter which flu vaccine you get, just get one.”